Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Jean-Baptiste Assie

Assistant-Professor

Centre Hospitalier Intercommunal de Créteil

France

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Articles (16)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (9)

Elaine Del Nery

Team Lead Phenotypic Drug Screening

Institut Curie

FRANCE

View details

Françoise Le Pimpec-Barthes

Professor

Université Paris Descartes Faculté de Médecine

FRANCE

View details

Christophe Blanquart

Research Director (CNRS)

Université de Nantes

FRANCE

View details

Boris Duchemann

Head

Assistance Publique - Hôpitaux de Paris

FRANCE

View details

Djillali Sahali

Université Paris-Est Créteil Val de Marne

FRANCE

View details

Pierantonio Laveneziana

Professeur des Universités - Praticien Hospitalier de Physiologie

Sorbonne Université Faculté de Médecine

FRANCE

View details

Francis LEVI

Professor

University of Warwick

UNITED KINGDOM

View details

simon valentin

Université de Lorraine

FRANCE

View details

Yurdagul Uzunhan

Sorbonne Université

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jean-Baptiste Assie

Research Interests

Make your next move.

Explore related searches

Articles (16)

Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma

The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy

Clinical outcomes of systemic anticancer therapies in solid cancer patients with liver and kidney transplant: an observational cross-sectional study

Management of advanced non-small cell lung cancer with <i>MET</i>-<i>exon</i>-<i>14</i>-skipping alterations: challenges remain after the Chrysalis study.

[Influence of smoking on the efficacy of immunotherapy in advanced lung cancers].

Papillon trial, a major advance in the management of patients with metastatic, mutated-EGFR exon 20 insertion non-small-cell lung cancer.

Recurrence as a small cell lung cancer transformation in a resected stage IIIA EGFR-mutated non-small cell lung cancer treated with adjuvant osimertinib: a case report.

Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis

Double immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case report.

First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced <i>EGFR</i>-mutated NSCLC: a meta-analysis of randomized phase III trials.

Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy

Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study.

Characteristics, management, and healthcare resources of patients with advanced non-small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis.

Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement.

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.

Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting.

Collaborators (9)

Elaine Del Nery

Françoise Le Pimpec-Barthes

Christophe Blanquart

Boris Duchemann

Djillali Sahali

Pierantonio Laveneziana

Francis LEVI

simon valentin

Yurdagul Uzunhan

Make your next move.

Jean-Baptiste Assie

Research Interests

Make your next move.

Explore related searches

Articles (16)

Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma

The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy

Clinical outcomes of systemic anticancer therapies in solid cancer patients with liver and kidney transplant: an observational cross-sectional study

Management of advanced non-small cell lung cancer with &lt;i&gt;MET&lt;/i&gt;-&lt;i&gt;exon&lt;/i&gt;-&lt;i&gt;14&lt;/i&gt;-skipping alterations: challenges remain after the Chrysalis study.

[Influence of smoking on the efficacy of immunotherapy in advanced lung cancers].

Papillon trial, a major advance in the management of patients with metastatic, mutated-EGFR exon 20 insertion non-small-cell lung cancer.

Recurrence as a small cell lung cancer transformation in a resected stage IIIA EGFR-mutated non-small cell lung cancer treated with adjuvant osimertinib: a case report.

Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis

Double immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case report.

First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced <i>EGFR</i>-mutated NSCLC: a meta-analysis of randomized phase III trials.

Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy

Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study.

Characteristics, management, and healthcare resources of patients with advanced non-small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis.

Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement.

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.

Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting.

Collaborators (9)

Elaine Del Nery

Françoise Le Pimpec-Barthes

Christophe Blanquart

Boris Duchemann

Djillali Sahali

Pierantonio Laveneziana

Francis LEVI

simon valentin

Yurdagul Uzunhan

Make your next move.

Management of advanced non-small cell lung cancer with <i>MET</i>-<i>exon</i>-<i>14</i>-skipping alterations: challenges remain after the Chrysalis study.